Cerebrolysin for acute ischaemic stroke

Summary: This study assessed the benefits and harms of Cerebrolysin, a drug derived from pig brains, for treating acute ischemic stroke by analyzing data from randomized controlled trials. The findings suggest that Cerebrolysin probably has little to no effect on overall death rates and serious adverse events, with moderate to very low certainty in the evidence.

Link: PubMed

Cerebrolysin: a multi-target drug for recovery after stroke

Summary: Cerebrolysin, a neuropeptide drug, shows promise in aiding recovery from brain injuries, particularly in moderate to severe stroke patients, and appears to enhance functional recovery when used alongside neurorehabilitation. Earlier trials in mildly affected stroke patients did not show clear benefits, but more recent studies support its efficacy and safety, suggesting the need for more rigorous future research.

Link: PubMed

Cerebrolysin for stroke, neurodegeneration, and traumatic brain injury: review of the literature and outcomes

Summary: Cerebrolysin shows potential in treating various neurological conditions such as strokes, neurodegenerative disorders, and brain injuries by stimulating important molecular pathways for brain regeneration. However, while it is used in over 50 countries and is generally safe, its effectiveness remains uncertain due to mixed clinical study results, highlighting the need for more robust research.

Link: PubMed

Cerebrolysin in Patients with Subarachnoid Hemorrhage: A Systematic Review and Meta-Analysis

Summary: A study was conducted to analyze the effect of the drug Cerebrolysin on Subarachnoid Hemorrhage (SAH) patients, showing a positive impact on reducing mortality rates. However, more extensive and randomized clinical trials are necessary to confirm these findings definitively.

Link: PubMed

Cerebrolysin: a review of its use in dementia

Summary: Cerebrolysin, a medication derived from pig brain peptides, has shown promise in improving cognition and overall outcomes in Alzheimer’s and vascular dementia patients, proving superior to placebo in several trials. While more research is needed to determine its long-term effectiveness and potential when combined with other treatments, it is generally well tolerated, with dizziness being the most common side effect.

Link: PubMed

Nanodelivery of cerebrolysin reduces pathophysiology of Parkinson’s disease

Summary: Parkinson’s disease (PD) affects over 10 million people globally, with increasing prevalence, especially among those over 50, and involves brain pathology like loss of dopaminergic neurons. The study discusses the potential of using nanotechnology to deliver treatments that protect the brain and restore the blood-brain barrier, highlighting research on the effectiveness of a drug called cerebrolysin.

Link: PubMed

Cerebrolysin potentiates the antidepressant effect of lithium in a rat model of depression

Summary: The study explored the combined effects of lithium and cerebrolysin in a rat depression model, finding that the treatment improved behavioral and neurochemical changes, as well as brain histopathology. Results suggest that adding cerebrolysin to lithium therapy could enhance the effectiveness of antidepressant treatments.

Link: ScienceDirect

Environmental enrichment and cerebrolysin improve motor and cognitive performance in a rat model of stroke, in conjunction with an increase in hippocampal AMPA but not NMDA receptor subunits

Summary: This study on stroke recovery in rats found that combining the drug cerebrolysin with an enriched environment improved both motor and cognitive performance, and reduced brain lesion size. The treatments increased specific receptor activity in the brain, suggesting potential synergistic benefits for stroke rehabilitation.

Link: ScienceDirect

Efficacy and safety of Cerebrolysin after futile recanalisation therapy in patients with severe stroke

Summary: The study investigated the effects of adding the neuroprotective agent Cerebrolysin to standard recanalisation therapy for stroke patients, finding it significantly reduced haemorrhagic complications and mortality rates compared to the control group. Despite no significant difference in primary clinical outcomes, the results suggest Cerebrolysin could offer protective benefits and maintain a good safety profile for acute stroke treatment.

Link: ScienceDirect

Cerebrolysin in Vascular Dementia: Improvement of Clinical Outcome in a Randomized, Double-Blind, Placebo-Controlled Multicenter Trial

Summary: This study found that adding Cerebrolysin to standard treatment significantly improved cognitive function and overall clinical outcomes in vascular dementia patients over 24 weeks, compared to a placebo. The treatment was safe and well tolerated, showing considerable improvements in primary parameters such as cognition and clinical functioning.

Link: ScienceDirect